Prostate Cancer - 5EU Drug Forecast and Market Analysis to 2023

Prostate Cancer - 5EU Drug Forecast and Market Analysis to 2023


  • Products Id :- GDHC344CFR
  • |
  • Pages: 191
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Prostate Cancer - 5EU Drug Forecast and Market Analysis to 2023

Summary

Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options. This report focuses on the current treatment landscape, unmet needs, pipeline assessment and market outlook for prostate cancer. . Since 2010, five new drugs have been approved for the treatment of CRPC: Dendreon's Provenge, Sanofi's Jevtana, Johnson & Johnson's Zytiga, Medivation/Astellas' Xtandi, and Bayer's Xofigo. During the forecast period from 2013-2023, GlobalData expects that nine new late-stage pipeline agents will launch, eight of which will be for the treatment of CRPC. As a result of this unprecedented level of clinical development, GlobalData predicts there will be massive changes in the CRPC treatment paradigm. In addition, due to the influx of new therapies, the size of the prostate cancer market across the nine major pharmaceutical markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada) will increase three-fold.

The 5EU is the second largest market for prostate cancer, after the US. This strong growth will be a result of the increasing incidence of prostate cancer as the population ages, increased sales resulting from the launch of eight new premium-priced pipeline products during the forecast period, and the label extension of Xtandi into the nmCRPC and hormone-sensitive prostate cancer patient populations.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of Prostate Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in 5EU from 2013-2023.

Analysis of the impact of key events as well the drivers and restraints affecting 5EU Prostate Cancer market.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Prostate Cancer.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2013-2023 in 5EU.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Introduction 11

2.1 Catalyst 11

2.2 Related Reports 11

2.3 Upcoming Related Reports 12

3 Disease Overview 13

3.1 Etiology and Pathophysiology 13

3.1.1 Etiology 13

3.1.2 Pathophysiology 13

3.2 Staging 14

3.3 Symptoms 18

3.4 Prognosis 18

3.5 Quality of Life 19

4 Disease Management 20

4.1 Diagnosis and Treatment Overview 20

4.1.1 Screening and Diagnosis 20

4.1.2 Treatment Guidelines and the Leading Prescribed Drugs 22

4.1.3 Clinical Practice 24

4.2 France 34

4.3 Germany 35

4.4 Italy 36

4.5 Spain 37

4.6 UK 38

5 Competitive Assessment 39

5.1 Overview 39

5.2 Product Profiles - Major Brands, Targeted Therapies 40

5.2.1 Zytiga (abiraterone acetate) 40

5.2.2 Xtandi (enzalutamide) 46

5.2.3 Xofigo (radium 223 dichloride) 51

5.3 Product Profiles - Major Brands, Chemotherapies 57

5.3.1 Jevtana (cabazitaxel) 57

5.4 Product Profiles - Major Brands, Therapeutic Vaccines 61

5.4.1 Provenge (sipuleucel-T) 61

5.5 Product Profiles - Major Brands, Hormone Therapies 65

5.5.1 Zoladex (goserelin acetate) 65

5.5.2 Lupron Depot (leuprolide acetate) 68

5.5.3 Eligard (leuprolide acetate) 71

5.5.4 Trelstar (triptorelin acetate) 73

5.5.5 Firmagon (degarelix) 75

5.5.6 Casodex (bicalutamide) 78

5.6 Product Profiles - Major Brands, Bone Therapies 81

5.6.1 Zometa (zoledronic acid) 81

5.6.2 Xgeva (denosumab) 83

6 Unmet Need and Opportunity 87

6.1 Overview 87

6.2 Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients 88

6.2.1 Unmet Need 88

6.2.2 Gap Analysis 89

6.2.3 Opportunity 90

6.3 Therapeutic Options for nmCRPC Patients 90

6.3.1 Unmet Need 90

6.3.2 Gap Analysis 91

6.3.3 Opportunity 91

6.4 Identification of Biomarkers to Predict Zytiga and Xtandi Resistance 92

6.4.1 Unmet Need 92

6.4.2 Gap Analysis 93

6.4.3 Opportunity 94

6.5 Defining the Best Sequence of Drugs to Manage mCRPC 94

6.5.1 Unmet Need 94

6.5.2 Gap Analysis 95

6.5.3 Opportunity 96

7 Pipeline Assessment 97

7.1 Overview 97

7.2 Product Profiles ? Immunotherapies 100

7.2.1 Yervoy (ipilimumab) 100

7.2.2 ProstVac 106

7.2.3 ProstAtak 111

7.2.4 DCVAC/PCa 116

7.2.5 ITK1 121

7.3 Product Profiles - Targeted Therapies 126

7.3.1 Custirsen Sodium 126

7.3.2 Tasquinimod 131

7.3.3 ARN-509 136

7.3.4 ODM-201 140

8 Market Outlook 146

8.1 5EU 146

8.1.1 Forecast 146

8.1.2 Key Events 150

8.1.3 Drivers and Barriers 151

9 Appendix 152

9.1 Bibliography 152

9.2 Abbreviations 171

9.3 Methodology 176

9.4 Forecasting Methodology 176

9.4.1 Diagnosed Prostate Cancer Patients 176

9.4.2 Percentage Drug-Treated Patients 177

9.4.3 Drugs Included in Each Therapeutic Class 177

9.4.4 Launch and Patent Expiry Dates 178

9.4.5 General Pricing Assumptions 179

9.4.6 Individual Drug Assumptions 180

9.4.7 Pricing of Pipeline Agents 183

9.5 Primary Research - KOLs Interviewed for This Report 185

9.6 Primary Research - Prescriber Survey 187

9.7 About the Authors 188

9.7.1 Analyst 188

9.7.2 Director of Oncology 188

9.7.3 Epidemiologist 189

9.7.4 Global Head of Healthcare 189

9.8 About GlobalData 190

9.9 Disclaimer 190

1.2 List of Figures

Figure 1: Disease Management Flowchart for Prostate Cancer 25

Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2013-2023 100

Figure 3: Yervoy's Clinical Development 102

Figure 4: Potential Clinical and Commercial Positioning of Yervoy 104

Figure 5: ProstVac's Clinical Development 108

Figure 6: Potential Clinical and Commercial Positioning of ProstVac 109

Figure 7: ProstAtak's Clinical Development 113

Figure 8: Potential Clinical and Commercial Positioning of ProstAtak 114

Figure 9: DCVAC/PCa's Clinical Development 117

Figure 10: Potential Clinical and Commercial Positioning of DCVAC/PCa 119

Figure 11: ITK1's Clinical Development 122

Figure 12: Potential Clinical and Commercial Positioning of ITK1 124

Figure 13: Custirsen Sodium's Clinical Development 128

Figure 14: Potential Clinical and Commercial Positioning of Custirsen Sodium 129

Figure 15: Tasquinimod's Clinical Development 133

Figure 16: Potential Clinical and Commercial Positioning of Tasquinimod 134

Figure 17: ARN-509's Clinical Development 138

Figure 18: Potential Clinical and Commercial Positioning of ARN-509 139

Figure 19: ODM-201's Clinical Development 142

Figure 20: Potential Clinical and Commercial Positioning of ODM-201 143

Figure 21: Sales for Prostate Cancer in the 5EU by Drug Class, 2013-2023 149

1.1 List of Tables

Table 1: TNM Classification of Prostate Cancer 16

Table 2: Prostate Cancer Staging 17

Table 3: Risk-Group Classifications Used in Prostate Cancer 18

Table 4: Most Commonly Used Treatment Guidelines for Prostate Cancer, 2014 22

Table 5: Most Commonly Prescribed Hormonal Therapies for Prostate Cancer, 2014 23

Table 6: Most Commonly Prescribed Chemotherapeutic, Drug, and Bone Therapies for CRPC, 2014 24

Table 7: Diagnosis and Treatment of Prostate Cancer, Country Profile - France 34

Table 8: Diagnosis and Treatment of Prostate Cancer, Country Profile - Germany 35

Table 9: Diagnosis and Treatment of Prostate Cancer, Country Profile - Italy 36

Table 10: Diagnosis and Treatment of Prostate Cancer, Country Profile - Spain 37

Table 11: Diagnosis and Treatment of Prostate Cancer, Country Profile - UK 38

Table 12: Leading Branded Drugs Used to Treat Prostate Cancer, 2014 40

Table 13: Product Profile - Zytiga 42

Table 14: Zytiga SWOT Analysis, 2014 44

Table 15: Global Sales Forecasts (USDm) for Zytiga, 2013?2023 45

Table 16: Product Profile - Xtandi 48

Table 17: Xtandi SWOT Analysis, 2014 50

Table 18: Global Sales Forecasts (USDm) for Xtandi, 2013?2023 51

Table 19: Product Profile - Xofigo 54

Table 20: Xofigo SWOT Analysis, 2014 55

Table 21: Global Sales Forecasts (USDm) for Xofigo, 2013?2023 56

Table 22: Product Profile - Jevtana 58

Table 23: Jevtana SWOT Analysis, 2014 59

Table 24: Global Sales Forecasts (USDm) for Jevtana, 2013?2023 60

Table 25: Product Profile - Provenge 63

Table 26: Provenge SWOT Analysis, 2014 64

Table 27: Global Sales Forecasts (USDm) for Provenge, 2013?2023 65

Table 28: Product Profile - Zoladex 66

Table 29: Zoladex SWOT Analysis, 2014 68

Table 30: Product Profile - Lupron 69

Table 31: Lupron SWOT Analysis, 2014 70

Table 32: Product Profile - Eligard 72

Table 33: Eligard SWOT Analysis, 2014 73

Table 34: Product Profile - Trelstar 74

Table 35: Trelstar SWOT Analysis, 2014 75

Table 36: Product Profile - Firmagon 76

Table 37: Firmagon SWOT Analysis, 2014 78

Table 38: Product Profile - Casodex 79

Table 39: Casodex SWOT Analysis, 2014 81

Table 40: Product Profile - Zometa 82

Table 41: Zometa SWOT Analysis, 2014 83

Table 42: Product Profile - Xgeva 85

Table 43: Xgeva SWOT Analysis, 2014 86

Table 44: Unmet Need and Opportunity in Prostate Cancer 88

Table 45: Drugs in Phase III Clinical Trials for Prostate Cancer 99

Table 46: Product Profile - Yervoy 102

Table 47: Yervoy SWOT Analysis, 2014 105

Table 48: Global Sales Forecasts (USDm) for Yervoy, 2013?2023 106

Table 49: Product Profile - ProstVac 107

Table 50: ProstVac SWOT Analysis, 2014 110

Table 51: Global Sales Forecasts (USDm) for ProstVac, 2013?2023 111

Table 52: Product Profile - ProstAtak 112

Table 53: ProstAtak SWOT Analysis, 2014 115

Table 54: Global Sales Forecasts (USDm) for ProstAtak, 2013?2023 116

Table 55: Product Profile - DCVAC/PCa 117

Table 56: DCVAC/PCa SWOT Analysis, 2014 120

Table 57: Global Sales Forecasts (USDm) for DCVAC, 2013?2023 121

Table 58: Product Profile - ITK1 122

Table 59: ITK1 SWOT Analysis, 2014 124

Table 60: Global Sales Forecasts (USDm) for ITK1, 2013?2023 125

Table 61: Product Profile - Custirsen Sodium 127

Table 62: Custirsen Sodium SWOT Analysis, 2014 130

Table 63: Global Sales Forecasts (USDm) for Custirsen Sodium, 2013?2023 131

Table 64: Product Profile - Tasquinimod 132

Table 65: Tasquinimod SWOT Analysis, 2014 135

Table 66: Global Sales Forecasts (USDm) for Tasquinimod, 2013?2023 136

Table 67: Product Profile - ARN-509 137

Table 68: ARN-509 SWOT Analysis, 2014 139

Table 69: Global Sales Forecasts (USDm) for ARN-509, 2013?2023 140

Table 70: Product Profile - ODM-201 141

Table 71: ODM-201 SWOT Analysis, 2014 144

Table 72: Global Sales Forecasts (USDm) for ODM-201, 2013-2023 145

Table 73: Sales Forecasts (USDm) for Prostate Cancer in the 5EU, 2013-2023 148

Table 74: Key Events Impacting Sales for Prostate Cancer in the 5EU, 2013-2023 150

Table 75: 5EU Prostate Cancer Market - Drivers and Barriers, 2013?2023 151

Table 76: Key Launch Dates, Marketed and Pipeline Prostate Cancer Drugs 178

Table 77: Key Patent Expiration or Loss of Market Exclusivity Dates, Marketed Prostate Cancer Drugs 178

Table 78: Average Body Weight and Surface Area Across the 9MM 180

Table 79: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 187

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

select a license

Single User License
USD 6995 INR 451737
Site License
USD 13990 INR 903474
Corporate User License
USD 20985 INR 1355211

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com